Results 181 to 190 of about 1,532,463 (338)

Holistic approach to substance‐induced psychosis

open access: yes
Addiction, EarlyView.
Julia M. Lappin   +2 more
wiley   +1 more source

On 3‐MMC: A Cathinone I Have Come to Know and Love

open access: yesAnthropology of Consciousness, EarlyView.
ABSTRACT This article attempts to complicate the mythology of a compound in a state of becoming. I will trace lightly its origins as a cultural disruptor and how I am implicated in this imperative. Introducing you to 3‐MMC will require multiple modes of storytelling and taking of liberties, drawing on literature reviews, practice‐based research, prose,
Carmen Ostrander
wiley   +1 more source

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
We conducted a nationwide, multicenter cohort study using a target trial emulation framework to compare baclofen and acamprosate in patients with compensated alcohol‐associated cirrhosis. After matching, baclofen initiation was associated with a higher 1‐year risk of major adverse liver outcomes, driven primarily by hepatic encephalopathy, particularly
Yee Hui Yeo   +13 more
wiley   +1 more source

A qualitative investigation of the lived experiences of adults with anxiety and related disorders and ADHD: Interconnectedness of symptoms and implications for improving care

open access: yesBritish Journal of Clinical Psychology, EarlyView.
Abstract Background Attention‐deficit/hyperactivity disorder (ADHD) is highly prevalent in adults with anxiety and related disorders (ARDs). Quantitative research on this clinical population is mixed, with some studies suggesting that anxiety is protective against some symptoms of ADHD and others in which co‐occurring ARDs and ADHD are linked to poorer
Arij Alarachi   +3 more
wiley   +1 more source

The Australia story: Current status and future challenges for the clinical applications of psychedelics

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt   +3 more
wiley   +1 more source

Cannabis Use Disorder

open access: yes, 2019
Iris, Balodis,, James, MacKillop,
openaire   +3 more sources

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

open access: yesBritish Journal of Pharmacology, EarlyView.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller   +3 more
wiley   +1 more source

Cannabis Use and Mental Health Problems [PDF]

open access: yes
This paper investigates whether cannabis use leads to worse mental health. To do so, we account for common unobserved factors affecting mental health and cannabis consumption by modeling mental health jointly with the dynamics of cannabis use.
Ours, J.C. van, Williams, J.
core   +1 more source

Home - About - Disclaimer - Privacy